Terms ending in 2028
Every in-force patent on Catalyst Biosciences, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,921,410 | Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes In force · High confidence | Attenua, Inc. | In force | High confidence | |
| US 8,765,726 | Use of Pyridone Derivatives in the Prevention or Treatment of Tissue or Organ Toxicity Induced by Cytotoxic Agents and Radiation In force · High confidence | Catalyst Biosciences, Inc. | In force | High confidence | |
| US 8,119,659 | (2S, 3R)-N-(2-((3-Pyridinyl)METHYL)-1-Azabicyclo[2.2.2]OCT-3-YL)BENZOFURAN-2-Carboxamide, Novel Salt Forms, and Methods of Use Thereof In force · High confidence | Trames Bio, Inc. | In force | High confidence | |
| US 8,541,446 | (2S,3R)-N-(2-((3-Pyridinyl)METHYL)-1-Azabicyclo[2.2.2]OCT-3-YL)BENZOFURN-2-Carboxamide, Novel Salt Forms, and Methods of Use Thereof In force · Medium confidence | Trames Bio, Inc. | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Catalyst Biosciences, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.